What is the ticker symbol for TransCode Therapeutics?

TransCode Therapeutics trades under the ticker RNAZ on NASDAQ.

What sector does TransCode Therapeutics operate in?

TransCode Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze RNAZ in a portfolio?

PortView shows RNAZ's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

TransCode Therapeutics (RNAZ) Stock Analysis

NASDAQHealthcareBiotechnology

$2.11+2.43%

1-year price historyRange $2.06 – $15.23

52-week range$2.11

$1.83$20.99

What TransCode Therapeutics does

TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.

Key metrics

Market cap

$2.23M

P/E (TTM)

-0.04

EPS (TTM)

$-52.52

Beta

1.24

Dividend yield

0.00%

Revenue / share

$0.00

50-day avg

$5.32

200-day avg

$7.54

52-week high

$20.99

52-week low

$1.83

CEO

Philippe Calais

ETFs linked to RNAZ

Broad-market and Healthcare sector ETFs an investor holding TransCode Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how RNAZ fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze RNAZ in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for TransCode Therapeutics?: TransCode Therapeutics trades under the ticker RNAZ on NASDAQ.
Which exchange is RNAZ listed on?: RNAZ is listed on NASDAQ.
What sector does TransCode Therapeutics operate in?: TransCode Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze RNAZ in a portfolio?: PortView shows RNAZ's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.